Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...
RNA drugs are the next frontier of medicine, but manufacturing them requires an expensive and labor-intensive process that limits production and produces metric tons of toxic chemical waste.
RNA-based medicines are transforming the way we treat disease—offering targeted, precision therapies for conditions ranging from rare genetic disorders to widespread chronic illnesses like diabetes, ...
The success of the mRNA-based vaccines against SARS-CoV-2 merely hint at the healthcare implications of mRNA technology. More mRNA-based vaccines are in the works, as are mRNA-based therapeutics for ...
While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and ...
NMU-Symphony™ is the next generation of the Nutcracker ® Manufacturing Unit, optimized for RNA-based individualized manufacturing of therapeutics The company has successfully completed manufacturing ...
"Soter Bio was built to support advanced therapeutic programs that depend on reliable, rapid, scalable input materials," said Mike Stewart, Founder and CEO of Soter Bio. "Partnering with Cellipont ...
SEOUL, Korea--(BUSINESS WIRE)--GenScript ProBio, a global multimodality CDMO and NuclixBio, a company developing treatments based on circular RNA, announced on 9th Nov that they have entered into a ...
The recognition of mRNA molecules as a transformative class of therapeutic drugs has soared, particularly with the development of COVID 19 mRNA vaccines. The cancer treatment landscape is similarly ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A spinout from George Church’s ...
Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results